rnk08954-01
KRAS G12D Mutation
Ranok Therapeutics (Hangzhou) Co., Ltd.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the KRAS G12D Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gfh375 Genfleet Therapeutics (Shanghai) Inc. | Phase 3 | B |
Docetaxel Genfleet Therapeutics (Shanghai) Inc. | Phase 3 | B |
Arv-806 Arvinas Inc. | Phase 1/2 | CC |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →